免疫療法の期待と知識の実践および臨床試験:横断研究
Beliz Bahar Karaoğlan1, Filiz Çay Şenler1,2
1Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye.
Immunotherapy
|January 14, 2026
まとめ
患者は、情報提供を受けていると感じているにもかかわらず、免疫チェックポイント阻害薬(ICI)に関する知識が不足していることが多い。臨床試験への参加は、理解度ではなく楽観主義を高めるが、患者教育の改善の必要性を強調している。
科学分野:
- 腫瘍学
- 免疫療法
- 患者教育
背景:
- 免疫チェックポイント阻害薬(ICI)に関して、知識と期待の間に大きなギャップが存在する。
- 外来クリニック vs. 臨床試験における患者の理解を比較した研究は限られている。
研究 の 目的:
- 外来クリニック vs. 臨床試験でICIを受けている患者の知識、期待、意思決定の好みを比較すること。
- ICIの認識された理解と実際の理解との間の乖離を特定すること。
主な方法:
- ICIで治療された固形腫瘍患者124名を対象とした横断研究。
- ICIの知識、副作用の認識、治療への期待、意思決定の好みを評価するために構造化された質問票を使用した。
- 外来クリニック(OC)および臨床試験(CT)参加者のデータを比較した。
主要な成果:
- 腫瘍内科医は、両群の患者にとって主要な情報源であった。;臨床試験(CT)患者は、外来(OC)患者よりも情報提供を受けていると感じていた(62.5% vs. 34.2%)が、客観的な知識は両群ともに乏しかった。;CT患者は、OC患者よりも治療への期待(91.7% vs. 64.5%)と満足度(75% vs. 46.1%)が高いと報告した。;ほとんどの患者は、ICI療法の継続中止に関する意思決定において、医師主導の決定を好んだ。
結論:
- 患者は、情報提供を受けていると感じている場合でも、ICIに関する正確な知識を欠いていることが多い。
- 臨床試験への参加は、患者の楽観主義と満足度を高める可能性があるが、必ずしも理解度を高めるわけではない。
- 知識と期待のギャップを埋め、共有意思決定を促進するためには、ターゲットを絞った患者教育が不可欠である。
関連する概念動画
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Cancer Vaccines
952
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
952
Cytotoxic T Cells-mediated Immune Response
6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Cross-reactivity
32.8K
Overview
32.8K


